Idorsia earns growth boost in Sfr330m deal

Investors poured into an accelerated trade in Swiss biopharmaceutical company Idorisia on Tuesday night, causing bookrunners to grow the deal by 1m shares. The success of the deal shows how highly investors value growth in the depressed economic environment of the Covid-19 pandemic.